#USA #Fremont #Alamar Biosciences #NULISAqpcr #AD 5-plex

Alamar Biosciences Launches NULISAqpcr AD 5-plex Assay

In a significant advancement for Alzheimer's disease research, Alamar Biosciences, a pioneering company in precision proteomics, has announced the launch of its Research Use Only (RUO) NULISAqpcr™ AD 5-plex Assay. Set to revolutionize the way biomarkers related to Alzheimer's are detected, this innovative assay allows the simultaneous quantitative measurement of five critical blood-based biomarkers from a single blood or plasma sample.

Key Features of the NULISAqpcr AD 5-plex Assay

The NULISAqpcr AD 5-plex Assay consolidates the measurement of several pivotal biomarkers into one streamlined format. It includes:

• - Brain-derived phosphorylated tau 217 (BD-pTau217)
• - Neurofilament light chain (NfL)
• - Amyloid-beta 42 (Aβ42)
• - Glial fibrillary acidic protein (GFAP)
• - APOE4 carrier status

This comprehensive approach enhances sensitivity and specificity while simplifying the testing process for researchers and clinicians. With the integrated measurement of these biomarkers, the assay facilitates detailed monitoring of various aspects of Alzheimer’s pathology, including amyloid and tau pathology, neurodegeneration, and inflammation.

Significance for Alzheimer's Research

The launch of the NULISAqpcr AD 5-plex Assay marks a significant milestone in the ongoing fight against Alzheimer's disease. Dr. Yuling Luo, founder and CEO of Alamar, emphasized the importance of this innovative tool in supporting the neuroscience community's efforts to enhance early screening, detection, and diagnosis of Alzheimer's disease.

Dr. Luo stated, "By combining these critical protein targets into a single assay with a streamlined workflow, we empower the neuroscience community to advance screening, early detection, and precision diagnoses for Alzheimer's disease."

Furthermore, Dr. Steven Williams, the company’s Chief Scientific Officer, pointed out how blood-based biomarkers are reshaping Alzheimer's research. He noted the benefits of a cheaper and more accessible means of accurate diagnosis, which is crucial for establishing eligibility for therapies. The NULISAqpcr AD 5-plex Assay enables researchers to generate a holistic view of the disease by measuring multiple Alzheimer's-related proteins in blood, each of which sheds light on unique aspects of the underlying pathology.

Collaborative Efforts to Enhance Patient Outcomes

Alamar Biosciences is committed to collaborating with a range of stakeholders including researchers, clinicians, and industry partners to unlock the potential of precision proteomics. The NULISAqpcr AD 5-plex Assay is available through Alamar's Technology Access Program, aimed at facilitating further research and development in the field.

This launch aims to not only benefit Alzheimer's research but also has implications for other neurodegenerative and cognitive disorders. By enhancing the understanding of these conditions, the technology could lead to better patient outcomes and treatments.

Conclusion

The introduction of the NULISAqpcr AD 5-plex Assay by Alamar Biosciences signifies a substantial leap forward in the quest for early detection and management of Alzheimer’s disease. As the life sciences community rallies to leverage this groundbreaking technology, the hope for improved patient outcomes and therapeutic strategies grows ever stronger. For additional insights and a comprehensive overview of Alamar's offerings, visit www.alamarbio.com.